Drug Trial Radar · NCT05378893
A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
153
Actual
Start
Jun 22, 2022
Primary completion
Oct 10, 2024
Study completion Jan 31, 2025
Sponsor
- Lead sponsor
- Zhejiang Doer Biologics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities. The objectives of the planned clinical investigation will be to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and multiple-ascending doses of DR10624 via subcutaneous (SubQ) injection in a randomized, placebo-controlled, double-blind study.
Conditions
- Healthy, Obesity, Metabolically
Interventions
DR10624 for injectionDrug
administered via subcutaneous injection
PlaceboDrug
administered via subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the Safety and TolerabilityTime frame: Baseline through Day 29 (Part 1 & Part 3); Pre-final dose on Day 78 through Day 106 (Part 2)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Zealand Clinical Research
Christchurch, Canterbury, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.